This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cheung, A. F. Articles by Jacks, T. Search for Related Content PubMed PubMed Citation Articles by Cheung, A. F. Articles by Jacks, T.

Regulated Expression of a Tumor-Associated Antigen Reveals Multiple Levels of T-Cell Tolerance in a Mouse Model of Lung Cancer

¹ Koch Institute and Department of Biology and ² Howard Hughes Medical Institute, Massachusetts Institute of Technology, Cambridge, Massachusetts

Requests for reprints: Tyler Jacks, 77 Massachusetts Avenue, E17-517, Cambridge, MA 02139. Phone: 617-253-0262; Fax: 617-253-9863; E-mail: tjacks{at}mit.edu.

Key Words: tumor antigen • T cells • mouse model • lung cancer • immune tolerance

Maximizing the potential of cancer immunotherapy requires model systems that closely recapitulate human disease to study T-cell responses to tumor antigens and to test immunotherapeutic strategies. We have created a new system that is compatible with Cre-LoxP–regulatable mouse cancer models in which the SIY antigen is specifically overexpressed in tumors, mimicking clinically relevant TAAs. To show the utility of this system, we have characterized SIY-reactive T cells in the context of lung adenocarcinoma, revealing multiple levels of antigen-specific T-cell tolerance that serve to limit an effective antitumor response. Thymic deletion reduced the number of SIY-reactive T cells present in the animals. When potentially self-reactive T cells in the periphery were activated, they were efficiently eliminated. Inhibition of apoptosis resulted in more persistent self-reactive T cells, but these cells became anergic to antigen stimulation. Finally, in the presence of tumors overexpressing SIY, SIY-specific T cells required a higher level of costimulation to achieve functional activation. This system represents a valuable tool in which to explore sources contributing to T-cell tolerance of cancer and to test therapies aimed at overcoming this tolerance. [Cancer Res 2008;68(22):9459–68]

This article has been cited by other articles:

				H. Jiang, H. C. Reinhardt, J. Bartkova, J. Tommiska, C. Blomqvist, H. Nevanlinna, J. Bartek, M. B. Yaffe, and M. T. Hemann The combined status of ATM and p53 link tumor development with therapeutic response Genes & Dev., August 15, 2009; 23(16): 1895 - 1909. [Abstract] [Full Text] [PDF]